DNA damage and repair in Alzheimer's disease

Current Alzheimer Research

Volumn 6, Issue 1, 2009, Pages 36-37

  Coppedè, Fabio ^a   Migliore, Lucia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Alzheimer's disease; DNA damage; DNA repair; Mild cognitive impairment; Oxidative dna damage

Indexed keywords

DNA; DNA BASE;

ALZHEIMER DISEASE; BASE PAIRING; BODY FLUID; BRAIN REGION; CANCER CELL CULTURE; DEMENTIA; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENETIC POLYMORPHISM; HUMAN; MILD COGNITIVE IMPAIRMENT; MITOSIS; NERVE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; CELL NUCLEUS; DNA DAMAGE; DNA REPAIR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NERVE DEGENERATION; OXIDATIVE STRESS;

EID: 62149107892     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787313970     Document Type: Review

References (99)

1. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 23: 213-31 (2002).
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA and Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60: 1119-22 (2003).
3. Azad NA, Al Bugami M and Loy-English I. Gender differences in dementia risk factors. Gend Med 4: 120-9 (2007).
4. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, et al. Sex differences in Alzheimer's disease. Neuropsychiatry 22: 1-15 (2008).
5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-8 (1999).
6. Findeis MA. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 116: 266-86 (2007).
7. Bertram L, McQueen MB, Mullin K, Blacker D and Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17-23 (2007).
8. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 274: 23223-8 (1999).
9. Santibáñez M, Bolumar F and García AM. Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies. Occup Environ Med 64: 723-32 (2007).
10. Van Den Heuvel C, Thornton E and Vink R. Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res 161: 303-16 (2007).
11. Burgener SC, Buettner L, Coen Buckwalter K, Beattie E, Bossen AL, Fick DM, et al. Evidence Supporting Nutritional Interventions for Persons in Early Stage Alzheimer's Disease (AD). J Nutr Health Aging 12: 18-21 (2008).
12. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 69: 1921-30 (2007).
13. Li JC and Kaminskas E. Deficient repair of DNA lesions in Alzheimer's disease fibroblasts. Biochem Biophys Res Commun 129: 733-38 (1985).
14. Robison SH, Munzer JS, Tandan R and Bradley WG. Alzheimer's disease cells exhibit defective repair of alkylating agent-induced DNA damage. Ann Neurol 21:250-8 (1987).
15. Fishel ML, Vasko MR and Kelley MR. DNA repair in neurons: so if they don't divide what's to repair? Mutat Res 614: 24-36 (2007).
16. Mecocci P, MacGarvey U and Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747-751 (1994).
17. Lyras L, Cairns NJ, Jenner A, Jenner P and Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 68: 2061-9 (1997).
18. Gabbita SP, Lovell MA and Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71: 2034-40 (1998).
19. Wang J, Xiong S, Xie C, Markesbery WR and Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93: 953-962 (2005).
20. Wang J, Markesbery WR and Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96: 825-832 (2006).
21. Lovell MA, Gabbita SP and Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72: 771-776 (1999).
22. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 59: 794- 798 (2002).
23. Kadioglu E, Sardas S, Aslan S, Isik E and Esat Karakaya A. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 9: 203-209 (2004).
24. Migliore L, Fontana I, Trippi F, Colognato R, Coppedè F, Tognoni G, et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26: 567-573 (2005).
25. Migliore L, Fontana I, Colognato R, Coppedè F, Siciliano G and Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26: 587-595 (2005).
26. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25: 823-9 (2005).
27. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, et al. Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J 20: 788-90 (2006).
28. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28: 3-9 (2008).
29. Lahiri DK, Maloney B, Basha MR, Ge YW and Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. Curr Alzheimer Res 4: 219-28 (2007).
30. Galic MA, Riazi K, Heida JG, Mouihate A, Fournier NM, Spencer SJ, et al. Postnatal inflammation increases seizure susceptibility in adult rats. J Neurosci 28: 6904-13 (2008).
31. Miller JW. Homocysteine, Alzheimer's disease, and cognitive function. Nutrition 16: 675-7 (2000).
32. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22: 1752-62 (2002).
33. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F and Scarpa S. Sadenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28: 195-204 (2005).
34. Mullaart E, Boerrigter ME, Ravid R, Swaab DF and Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11: 169-73 (1990).
35. Su JH, Deng G and Cotman CW. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 774: 193-9 (1997).
36. Suram A, Hegde ML and Rao KS. A new evidence for DNA nicking property of amyloid beta- peptide (1-42): relevance to Alzheimer's disease. Arch Biochem Biophys 463: 245-52 (2007).
37. Moreira PI, Nunomura A, Honda K, Aliev G, Casadenus G, Zhu X, et al. The key role of oxidative stress in Alzheimer's disease. In Oxidative stress and neurodegenerative disorders. Ali QG, Hassan PS (Eds:), Elsevier, Amsterdam, pp. 451-466 (2007).
38. Hegde ML, Anitha S, Latha KS, Mustak MS, Stein R, Ravid R, et al. First evidence for helical transitions in supercoiled DNA by amyloid Beta Peptide (1-42) and aluminum: a new insight in understanding Alzheimer's disease. J Mol Neurosci 22: 19-31 (2004).
39. Lovell MA, Ehmann WD, Mattson MP and Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-61 (1997).
40. Markesbery WR and Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-6 (1998).
41. McGrath LT, McGleenon BM, Brennan S, McColl D, McILroy S and Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94: 485-90 (2001).
42. Williams TI, Lynn BC, Markesbery WR and Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27: 1094-9 (2006).
43. Pamplona R, Dalfó E, Ayala V, Bellmunt MJ, Prat J, Ferrer I, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280: 21522-30 (2005).
44. Götz ME, Wacker M, Luckhaus C, Wanek P, Tatschner T, Jellinger K, et al. Unaltered brain levels of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal in Alzheimer's disease. Neurosci Lett 324: 49-52 (2002).
45. Liu X, Lovell MA and Lynn BC. Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nanoelectrospray tandem mass spectrometry. Chem Res Toxicol 19: 710-8 (2006).
46. Liu X, Lovell MA and Lynn BC. Development of a method for quantification of acrolein- deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal Chem 77: 5982-9 (2005).
47. DiMauro S and Schon EA. Mitochondrial respiratory-chain diseases: mitochondrial respiratory-chain diseases. N Engl J Med 348: 2656-68 (2003).
48. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 23: 471-6 (1994).
49. Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17: 171-184 (1993).
50. Coskun PE, Beal MF and Wallace DC. Alzheimer's brains harbour somatic mtDNA control- region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 101: 10726-31 (2004).
51. Chinnery PF, Taylor R, Howell N, Brown DT, Parsons TJ and Turnbull DM. Point mutations of the mtDNA control region in normal and neurodegenerative human brains. Am J Hum Genet 68: 529-32 (2001).
52. Elson JL, Herrnstadt C, Preston G, Thal L, Morris CM, Edwardson JA, et al. Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet 12: 1-14 (2006).
53. Nagy Z, Esiri MM and Smith AD. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 87: 731-39 (1998).
54. Yang Y, Mufson EJ and Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23: 2557-63 (2003).
55. Krantic S, Mechawar N, Reix S and Quirion R. Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci 28: 670-676 (2005).
56. Wang H, Yu SW, Koh DW, Lew J, Coombs C, Bowers W, et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci 24: 10963-73 (2004).
57. Kauppinen TM and Swanson RA. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145: 1267-72 (2007).
58. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89: 35-41 (1995).
59. Adamec E, Vonsattel JP and Nixon RA. DNA strand breaks in Alzheimer's disease. Brain Res 849: 67-77 (1999).
60. Love S, Barber R and Wilcock GK. Increased poly(ADPribosyl) ation of nuclear proteins in Alzheimer's disease. Brain 122: 247-53 (1999).
61. Adamczyk A, Jeśko H and Strosznajder RP. Alzheimer's disease related peptides affected cholinergic receptor mediated poly(ADP-ribose) polymerase activity in the hippocampus. Folia Neuropathol 43: 139-42 (2005).
62. Bradley WG, Polinsky RJ, Pendlebury WW, Jones SK, Nee LE, Bartlett JD, et al. DNA repair deficiency for alkylation damage in cells from Alzheimer's disease patients. Prog Clin Biol Res 317: 715-32 (1989).
63. Furuta A, Iida T, Nakabeppu Y and Iwaki T. Expression of hMTH1 in the hippocampi of control and Alzheimer's disease. Neuroreport 12: 2895-9 (2001).
64. Kajitani K, Yamaguchi H, Dan Y, Furuichi M, Kang D and Nakabeppu Y. MTH1, an oxidized purine nucleoside triphosphatase, suppresses the accumulation of oxidative damage of nucleic acids in the hippocampal microglia during kainate-induced excitotoxicity. J Neurosci 26: 1688-98 (2006).
65. Jacobsen E, Beach T, Shen Y, Li R and Chang Y. Deficiency of the Mre11 DNA repair complex in Alzheimer's disease brains. Brain Res Mol Brain Res 128: 1-7 (2004).
66. Shackelford DA. DNA end joining activity is reduced in Alzheimer's disease. Neurobiol Aging 27: 596-605 (2006).
67. Lovell MA, Xie C and Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res 855: 116-23 (2000).
68. Fleck O and Nielsen O. DNA repair. J Cell Sci 117: 515-7 (2004).
69. Weissman L, de Souza-Pinto NC, Stevnsner T and Bohr VA. DNA repair, mitochondria, and neurodegeneration. Neuroscience 145: 1318-29 (2007).
70. Dianov GL, Sleeth KM, Dianova II and Allinson SL. Repair of abasic sites in DNA. Mutat Res 531: 157-63 (2003).
71. Tan Z, Sun N and Schreiber SS. Immunohistochemical localization of redox factor-1 (Ref-1) in Alzheimer's hippocampus. Neuroreport 9: 2749-52 (1998).
72. Davydov V, Hansen LA and Shackelford DA. Is DNA repair compromised in Alzheimer's disease? Neurobiol Aging 24: 953-68 (2003).
73. Iida T, Furuta A, Nishioka K, Nakabeppu Y and Iwaki T. Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. Acta Neuropathol 103: 20-5 (2002).
74. Weissman L, Jo DG, Sørensen MM, de Souza-Pinto NC, Markesbery WR, Mattson MP, et al. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res 35: 5545-55 (2007).
75. Weissman L, de Souza-Pinto NC, Mattson MP and Bohr VA. DNA base excision repair activities in mouse models of Alzheimer's disease. Neurobiol Aging [Epub ahead of print] (2008).
76. Coppedè F, Mancuso M, Lo Gerfo A, Manca ML, Petrozzi L, Migliore L, et al. A Ser326Cys polymorphism in the DNA repair gene hOGG1 is not associated with sporadic Alzheimer's disease. Neurosci Lett 414(3): 282-5 (2007).
77. Weiss JM, Goode EL, Ladiges WC and Ulrich CM. Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 42: 127-41 (2005).
78. Coppedè F, Mancuso M, Lo Gerfo A, Carlesi C, Piazza S, Rocchi A, et al. Association of the hOGG1 Ser326Cys polymorphism with sporadic amyotrophic lateral sclerosis. Neurosci Lett 420: 163-8 (2007).
79. Vodicka P, Stetina R, Polakova V, Tulupova E, Naccarati A, Vodickova L, et al. Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 28: 657-64 (2007).
80. Mao G, Pan X, Zhu BB, Zhang Y, Yuan F, Huang J, et al. Identification and characterization of OGG1 mutations in patients with Alzheimer's disease. Nucleic Acids Res 35: 2759-66 (2007).
81. Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, et al. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med In Press (2008).
82. Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci USA 96: 13300-5 (1999).
83. de Souza-Pinto NC, Eide L, Hogue BA, Thybo T, Stevnsner T, Seeberg E, et al. Repair of 8-oxodeoxyguanosine lesions in mitochondrial dna depends on the oxoguanine dna glycosylase (OGG1) gene and 8-oxoguanine accumulates in the mitochondrial dna of OGG1-defective mice. Cancer Res 61: 5378-81 (2001).
84. Osterod M, Hollenbach S, Hengstler JG, Barnes DE, Lindahl T and Epe B. Age-related and tissue-specific accumulation of oxidative DNA base damage in 7,8-dihydro-8- oxoguanine-DNA glycosylase (Ogg1) deficient mice. Carcinogenesis 22: 1459-63 (2001).
85. Rozalski R, Gackowski D, Roszkowski K, Foksinski M and Olinski R. The level of 8- hydroxyguanine, a possible repair product of oxidative DNA damage, is higher in urine of cancer patients than in control subjects. Cancer Epidemiol Biomarkers Prev 11: 1072-5 (2002).
86. Kunisada M, Sakumi K, Tominaga Y, Budiyanto A, Ueda M, Ichihashi M, et al. 8- Oxoguanine formation induced by chronic UVB exposure makes Ogg1 knockout mice susceptible to skin carcinogenesis. Cancer Res 65: 6006-10 (2005).
87. Risom L, Dybdahl M, Møller P, Wallin H, Haug T, Vogel U, et al. Repeated inhalations of diesel exhaust particles and oxidatively damaged DNA in young oxoguanine DNA glycosylase (OGG1) deficient mice. Free Radic Res 41: 172-81 (2007).
88. Kinoshita A, Wanibuchi H, Morimura K, Wei M, Nakae D, Arai T, et al. Carcinogenicity of dimethylarsinic acid in Ogg1-deficient mice. Cancer Sci 98: 803-14 (2007).
89. Cardozo-Pelaez F, Cox DP and Bolin C. Lack of the DNA repair enzyme OGG1 sensitizes dopamine neurons to manganese toxicity during development. Gene Expr 12: 315-23 (2005).
90. Larsen E, Reite K, Nesse G, Gran C, Seeberg E and Klungland A. Repair and mutagenesis at oxidized DNA lesions in the developing brain of wild-type and Ogg1-/- mice. Oncogene 25: 2425-32 (2006).
91. Imam SZ, Karahalil B, Hogue BA, Souza-Pinto NC and Bohr VA. Mitochondrial and nuclear DNA-repair capacity of various brain regions in mouse is altered in an age- dependent manner. Neurobiol Aging 27: 1129-36 (2006).
92. El-Khamisy SF, Masutani M, Suzuki H and Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31: 5526-33 (2003).
93. Hu Z, Ma H, Chen F, Wei Q and Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 14: 1810-8 (2005).
94. Doǧru-Abbasoǧlu S, Aykaç-Toker G, Hanagasi HA, Gürvit H, Emre M and Uysal M. The Arg194Trp polymorphism in DNA repair gene XRCC1 and the risk for sporadic late-onset Alzheimer's disease. Neurol Sci 28: 31-4 (2007).
95. Fleck O and Nielsen O. DNA repair. J Cell Sci 117: 515-7 (2004).
96. Dogru-Abbasoglu S, Inceoglu M, Parildar-Karpuzoglu H, Hanagasi HA, Karadag B, and Gurvit H. Polymorphisms in the DNA repair genes XPD (ERCC2) and XPF (ERCC4) are not associated with sporadic late-onset Alzheimer's disease. Neurosci Lett 404: 258-61 (2006).
97. Clarkson SG and Wood RD. Polymorphisms in the human XPD (ERCC2) gene, DNA repair capacity and cancer susceptibility: an appraisal. DNA Repair (Amst) 4: 1068-74 (2005).
98. Subba Rao K. Mechanisms of disease: DNA repair defects and neurological disease. Nat Clin Pract Neurol 3: 162-72 (2007).
99. Greenway MJ, Alexander MD, Ennis S, Traynor BJ, Corr B, Frost E, et al. A novel candidate region for ALS on chromosome 14q11.2. Neurology 63: 1936-8 (2004).